Antibiotic Resistant Infection Clinical Trial
Official title:
Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients
Verified date | November 2015 |
Source | Mahidol University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Thailand: Ethical Committee |
Study type | Interventional |
The purpose of this study is to determine 2% chlorhexidine wipes are effective in preventing of colonization of multi-drug resistant bacteria in intensive care unit patients.
Status | Completed |
Enrollment | 481 |
Est. completion date | April 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 95 Years |
Eligibility |
Inclusion Criteria: - Age > 18 years - Admission in critical care unit eg. ICU, respiratory care unit, Cardiac care unit with in 24 hours - Expected duration of critical care unit admission > 48 hours Exclusion Criteria: - History of chlorhexidine allergy |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Thailand | Faculty of Medicine Siriraj Hospital, Mahidol University | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Mahidol University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The overall rate of Multidrug resistant bacteria acquisition at 7 days after received 2% chlorhexidine wipe bathing versus with soap bathing | 7 days after received 2% chlorhexidine wipes,the microbiology laboratory will process surveillance specimens using either standard culture-based at both nostrils, axillar, groins, rectum | 7 days after recieved 2% chlorhexidine wipes | Yes |
Secondary | The overall rate of hospital-acquired bloodstream infections per 1000 patient-days with chlorhexidine wipe bathing versus with soap bathing | 48 hours after recieved 2% chlorhexidine wipes | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
Recruiting |
NCT02922998 -
CD64 and Antibiotics in Human Sepsis
|
N/A | |
Completed |
NCT04212403 -
Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)
|
N/A | |
Recruiting |
NCT05502380 -
Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery
|
Phase 3 | |
Withdrawn |
NCT04462133 -
Optimal Tailored Treatment for H. Pylori Infection
|
N/A | |
Completed |
NCT03535324 -
Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT)
|
N/A | |
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Withdrawn |
NCT04230746 -
Effect of Antibiotics on Urinary Microbiome
|
Early Phase 1 | |
Active, not recruiting |
NCT03865706 -
Inulin for Infections in the Intensive Care Unit
|
Phase 2 | |
Not yet recruiting |
NCT06028217 -
Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
|
||
Completed |
NCT05391035 -
The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
|
||
Recruiting |
NCT05224401 -
Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs
|
Phase 3 | |
Not yet recruiting |
NCT03855709 -
Antibiotic-resistant Bacterial Infection of Hepatic Patients
|
||
Terminated |
NCT03535272 -
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
|
Phase 3 | |
Recruiting |
NCT05902299 -
Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions
|
||
Recruiting |
NCT05293483 -
The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia
|
||
Recruiting |
NCT05561504 -
Helicobacter Pylori Local Prevalence and Antibiotic Resistance
|
||
Recruiting |
NCT03606031 -
Digestive Microbiota Transplant
|
||
Completed |
NCT01573195 -
Merck IISP Stewardship Grant for Antibiotic Best Practices
|
Phase 4 | |
Not yet recruiting |
NCT03857295 -
Infections Following NeuroSurgery (INS)
|